Upperton Pharma Solutions has expanded its GMP manufacturing capabilities with the installation of a Fill2Weight gravimetric powder filling system from 3P innovation at its 60,000-square-foot facility in Nottingham, UK.
The addition strengthens Upperton’s capacity for the precise and efficient filling of oral solid, nasal, pulmonary, and parenteral dosage forms, supporting the company’s formulation development and clinical manufacturing services. The Fill2Weight system uses gravimetric dosing technology to ensure exact powder weights for each unit, improving reproducibility for low-dose and high-potency active pharmaceutical ingredients (APIs) as well as complex powder formulations.
The system’s flexibility allows for accurate filling of a broad range of powder types and fill weights, including applications for capsules and dry powder inhalers. By adopting this technology, Upperton aims to streamline development timelines and reduce risk for clients developing small-molecule and high-potency products for clinical trials.
Ian Lafferty, Chief Technical Officer at Upperton, said the addition “marks a significant advancement in our GMP manufacturing capabilities, increasing our capacity to manufacture small-molecule and high-potency medicines for clinical trials.”
Tom French, Head of Process Technologies at 3P innovation, noted that Upperton’s investment underscores the industry’s demand for systems capable of delivering precise dosing performance for challenging powder formulations.